Theranostic Concepts: More Than Just a Fashion Trend—Introduction and Overview

Herrmann, Ken; Larson, Steven M.

doi:10.2967/jnumed.117.199570

Cited by 42 publications

(23 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…“Theranostic imaging” (therapy: Greek therapeia: to treat medically; knowledge: Greek: gnosis ) refers to the combination of a predictive biomarker with a therapeutic agent [ 21 ]. The theranostic concept based on PSMA overexpression led to the use of PSMA ligands for systemic therapy in patients with castration-resistant (CR) PC.…”

Section: Introductionmentioning

confidence: 99%

Current status of theranostics in prostate cancer

Virgolini

Decristoforo

Haug

et al. 2017

Eur J Nucl Med Mol Imaging

132

View full text Add to dashboard Cite

The aim of this review is to report on the current status of prostate-specific membrane antigen (PSMA)-directed theranostics in prostate cancer (PC) patients. The value of 68Ga-PSMA-directed PET imaging as a diagnostic procedure for primary and recurrent PC as well as the role of evolving PSMA radioligand therapy (PRLT) in castration-resistant (CR)PC is assessed. The most eminent data from mostly retrospective studies currently available on theranostics of prostate cancer are discussed. The current knowledge on 68Ga-PSMA PET/CT implicates that primary staging with PET/CT is meaningful in patients with high-risk PC and that the combination with pelvic multi parametric (mp)MR (or PET/mpMR) reaches the highest impact on patient management. There may be a place for 68Ga-PSMA PET/CT in intermediate-risk PC patients as well, however, only a few data are available at the moment. In secondary staging for local recurrence, 68Ga-PSMA PET/mpMR is superior to PET/CT, whereas for distant recurrence, PET/CT has equivalent results and is faster and cheaper compared to PET/mpMR. 68Ga-PSMA PET/CT is superior to 18F / 11Choline PET/CT in primary staging as well as in secondary staging. In patients with biochemical relapse, PET/CT positivity is directly associated with prostate-specific antigen (PSA) increase and amounts to roughly 50% when PSA is raised to ≤0.5 ng/ml and to ≥90% above 1 ng/ml. Significant clinical results have so far been achieved with the subsequent use of radiolabeled PSMA ligands in the treatment of CRPC. Accumulated activities of 30 to 50 GBq of 177Lu-PSMA ligands seem to be clinically safe with biochemical response and PERCIST/RECIST response in around 75% of patients along with xerostomia in 5–10% of patients as the only notable side effect. On the basis of the current literature, we conclude that PSMA-directed theranostics do have a major clinical impact in diagnosis and therapy of PC patients. We recommend that 68Ga-PSMA PET/CT should be performed in primary staging together with pelvic mpMR in high-risk patients and in all patients for secondary staging, and that PSMA-directed therapy is a potent strategy in CRPC patients when other treatment options have failed. The combination of PSMA-directed therapy with existing therapy modalities (such as 223Ra-chloride or androgen deprivation therapy) has to be explored, and prospective clinical multicenter trials with theranostics are warranted.

show abstract

Section: Introductionmentioning

confidence: 99%

Current status of theranostics in prostate cancer

Virgolini

Decristoforo

Haug

et al. 2017

Eur J Nucl Med Mol Imaging

132

View full text Add to dashboard Cite

show abstract

“…The drawbacks of conventional therapy is that the normal cells also get affected by chemotherapeutic action resulting in several side effects.The idea of using a radioactive compound for diagnostic imaging, target-expression confirmation, and radionuclide therapy dates back to 1946, when Seidlin et al published the first study on radioiodine therapy for metastatic thyroid cancer. 4 In 19 th century, Iodine131 was identified as first theranostic agent in the treatment of thyrotoxicosis. This isotope when radiated to the patient, it not only identify the benign condition but also helps in the treatment of thyroid cancer.…”

Section: Conceptuals Of Theranosticsmentioning

confidence: 99%

A Review on Theranostics: An Approach to Targeted Diagnosis and Therapy

Shrivastava

Jain

Kumar

et al. 2019

Asian J Pharm Res Dev

View full text Add to dashboard Cite

Emerging as a targeted, safe, and efficient pharmacotherapy is the approach of theranostics, which focuses on patient centered care. It is a combination of diagnosis and therapeutics. Theranostics is a new field of medicine which combines specific targeted therapy based on specific targeted diagnostic tests. With a key focus on patient centered care, theranostics provides a transition from conventional medicine to a contemporary personalized and precision medicine approach. The theranostics paradigm involves using nanoscience to unite diagnostic and therapeutic applications to form a single agent, allowing for diagnosis, drug delivery and treatment response monitoring. The theranostics medicine can achieve systemic circulation, evade host defenses and deliver the drug and diagnostic agents at the targeted site to diagnose and treat the disease at cellular and molecular level.

show abstract

“…Свидетельством бурного развития данного направления является появление огромного количества публикаций, посвященных этой проблеме. Например, поиск в ресурсе PubMed показал, что понятие «тераностика» впервые появилось в 2002 г. К 2017 г. поиск со словом «тераностика» давал свыше 3800 результатов [38]. Наиболее наглядно сущность дисциплины -радионуклидная тераностика -проявляется при рассмотрении сути метода диагностики и лечения гипертиреоза и рака щитовидной железы радиоактивным йодом.…”

Section: радиоактивный йод против рака щитовидной железыunclassified

Radioiodine therapy for thyroid cancer

Rybakov¹

2019

CE&ES

View full text Add to dashboard Cite

Theranostic Concepts: More Than Just a Fashion Trend—Introduction and Overview

Cited by 42 publications

References 18 publications

Current status of theranostics in prostate cancer

Current status of theranostics in prostate cancer

A Review on Theranostics: An Approach to Targeted Diagnosis and Therapy

Radioiodine therapy for thyroid cancer

Contact Info

Product

Resources

About